US20020037305A1 - Cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders - Google Patents
Cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders Download PDFInfo
- Publication number
- US20020037305A1 US20020037305A1 US09/965,795 US96579501A US2002037305A1 US 20020037305 A1 US20020037305 A1 US 20020037305A1 US 96579501 A US96579501 A US 96579501A US 2002037305 A1 US2002037305 A1 US 2002037305A1
- Authority
- US
- United States
- Prior art keywords
- solution
- ester
- alcohol
- retinoic acid
- glyco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 210000005036 nerve Anatomy 0.000 title claims abstract description 5
- 239000000203 mixture Substances 0.000 title claims description 47
- 239000002537 cosmetic Substances 0.000 title claims description 26
- 230000001857 anti-mycotic effect Effects 0.000 title claims description 8
- 239000002543 antimycotic Substances 0.000 title claims description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 45
- 229960001727 tretinoin Drugs 0.000 claims abstract description 45
- 229930002330 retinoic acid Natural products 0.000 claims abstract description 44
- 150000002148 esters Chemical class 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 27
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 230000002262 irrigation Effects 0.000 claims abstract description 4
- 238000003973 irrigation Methods 0.000 claims abstract description 4
- 230000001066 destructive effect Effects 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 claims abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 73
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 44
- 239000006071 cream Substances 0.000 claims description 19
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 18
- 206010000496 acne Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 208000032544 Cicatrix Diseases 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 231100000241 scar Toxicity 0.000 claims description 13
- 230000037387 scars Effects 0.000 claims description 13
- 208000017520 skin disease Diseases 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 206010040925 Skin striae Diseases 0.000 claims description 11
- 208000031439 Striae Distensae Diseases 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000005886 esterification reaction Methods 0.000 claims description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 9
- 229960004889 salicylic acid Drugs 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical group ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 8
- 229920000742 Cotton Polymers 0.000 claims description 7
- 125000004494 ethyl ester group Chemical group 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003377 acid catalyst Substances 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 210000004392 genitalia Anatomy 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 150000005846 sugar alcohols Polymers 0.000 claims description 4
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960000905 indomethacin Drugs 0.000 claims description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
- 229960000916 niflumic acid Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- JDSQBDGCMUXRBM-UHFFFAOYSA-N 2-[2-(2-butoxypropoxy)propoxy]propan-1-ol Chemical compound CCCCOC(C)COC(C)COC(C)CO JDSQBDGCMUXRBM-UHFFFAOYSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000006872 improvement Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 11
- 206010040844 Skin exfoliation Diseases 0.000 description 10
- 201000004681 Psoriasis Diseases 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000009835 boiling Methods 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000010195 Onychomycosis Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000101040 Pityriasis Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- -1 glycol ester Chemical class 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 201000005882 tinea unguium Diseases 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 230000003501 anti-edematous effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000003236 psychic effect Effects 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012397 Depression suicidal Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 241000842539 Rhagades Species 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000036562 nail growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- the present invention relates to cosmetic compositions which may be applied to any part of the skin of the human body, including the scalp and genital organs, for effectively reducing and/or gradually eliminating unsightly skin disorders such as stretch marks, acne, scars, dark spots and incipient baldness, and which are also highly effective in treating mycosis and psoriasis.
- the present invention also relates to a cosmetic method of employing such compositions.
- a cosmetic, antimycotic composition for skin application in particular for treating unsightly skin disorders such as acne, stretch marks, scars and dark spots;
- the composition also comprises, in combination, the ethyl ester of retinoic acid and hydroquinone, both also dissolved in said glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solution.
- said glyco-alcohol solution comprises propylene glycol and, in lesser proportions, ethyl alcohol; and also contains propylene glycol ether.
- one composition according to the invention comprises a glyco-alcohol solution of 0.10 to 0.25 N of ethyl ester of retinoic acid, and 0.15 to 0.30 N of glycopropylene ester of retinoic acid.
- said glyco-alcohol solution presents a propylene glycol base, and also contains 0.001 to 0.002 N of ethyl-glycopropylene ether.
- retinoic acid as such is already known as a product for the treatment of acne, and is preferably obtained from its ethyl ester. Its direct “clinical” use, however, in the form of ethyl and, more especially, glycopropyl ester, and its association with hydroquinone in a glyco- and/or hydro-alcohol solution, are entirely new, and have surprisingly resulted in a product which is equally effective in the treatment of any other unsightly skin disorder, and which produces a marked peeling effect (desquamation of the surface layers of the skin) with a visible improvement in the tone, firmness and luminosity of the skin, a visible reduction of small wrinkles, and a marked reduction of deeper wrinkles, together with a reduction in excess sebum secretion.
- composition according to the invention provides for a marked improvement after only a few applications (five on average) and eventually total elimination.
- the composition according to the invention is also a highly effective antimycotic for curing diseases such as pityriasis, versicolor and onychomycosis after only two/four applications (one a week), and also provides for a marked improvement and for eventually curing psoriasis.
- composition according to the invention may be marketed and used in the form of a solution applied using cotton cloth, cotton-wool, tissues or sponges soaked in the solution, or may comprise solid or semisolid excipients in which the glyco-alcohol solution is dispersed to form a cream, in which case, however, the peeling effect is reduced or entirely eliminated.
- the composition therefore also comprises solid or semisolid excipients in which 2-10% by weight of said glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solution of said esters of retinoic acid is dispersed, so that the composition according to the invention is in the form of a cream.
- composition according to the invention may optionally comprise a cortisone, an anti-inflammatory substance, one or more liposoluble vitamins, and salicylic acid as such or in the form of glycol ester. More specifically, said anti-inflammatory substance is selected from the group comprising: niflumic acid, indomethacin and naproxene.
- composition according to the invention may comprise sodium heparin in gel form to enhance the anti-edema effect.
- the composition according to the invention is prepared by producing an esterification reaction between retinoic acid and propylene glycol in a glyco-alcohol solution with a large excess of propylene glycol, so that substantially all the retinoic acid in the solution is esterified; and, after the esterification reaction, the solution is used as such, without removing the surplus reactants or the reaction products.
- the reaction is preferably conducted in the presence of 1.35% to 23.9% by weight of hydroquinone in the glyco-alcohol solution, and by catalyzing the reaction by heating the reaction mixture and/or by performing the reaction in the presence of an acid substance, e.g. salicylic acid, hydrochloric acid or thionyl chloride.
- a cosmetic method in accordance with the present invention is characterized in that:
- a glycol or glyceric ester of retinoic acid is prepared in a glyco-alcohol solution by esterifying the acid with the corresponding polyalcohol and operating with a large excess of polyalcohol in the presence of hydroquinone;
- the resulting solution containing the ester produced by the reaction, and possibly aged in atmospheric air at ambient temperature, is subsequently applied to the skin region for treatment to produce surface peeling of the region.
- the glycopropylene ester of retinoic acid is prepared in a first solution comprising propylene glycol as the only solvent and containing 0 to 8.5% by weight, of the total weight of the solution, of hydroquinone, by dissolving, in said solution, 0.01 to 4% by weight, of the total weight of the solution, of retinoic acid; and said solution containing the prepared ester is subsequently applied to the skin region for treatment.
- a mixture of glycopropylene and ethyl esters of retinoic acid is prepared in a second solution comprising equal proportions by volume of ethyl alcohol and propylene glycol as solvents and containing 1 to 13% by weight, of the total weight of the solution, of hydroquinone, by dissolving, in said solution, 0.01 to 0.13% by weight, of the total weight of the solution, of retinoic acid; and said solution containing the prepared mixture of esters is then applied to the skin region for treatment.
- said solutions containing the reaction products and formed as in the previous embodiments are mixed together to a predetermined ratio; the resulting solution being stored stably in a refrigerator, and being applied in a predetermined quantity to the skin region by means of a sponge, cotton cloth, cotton-wool or any other appropriate means soaked in the solution.
- the two solutions are preferably mixed to a ratio of 1:1 to 1:1.5 by volume.
- the combined solution formed in the third embodiment of the cosmetic method according to the invention is applied once a day for a period of 6 to 10 days, said application cycle being repeatable after a suspension of 4 to 6 months, or is applied twice a week for 6 to 7 weeks.
- appropriate excipients may be added to the combined solution to form a cream containing 2 to 10% by weight of said solution; and the cream is applied as such, with no appreciable peeling effect, once a day for a period of 3 to 6 months.
- the solution and the cream may be applied jointly in the amounts and in the manner prescribed.
- said esterification reaction may be performed in the absence of hydroquinone in said glyco-alcohol solution, or by subsequently eliminating the hydroquinone from said reaction solution; the resulting solution then being diluted up to 30 times in propylene glycol and used to treat particularly delicate skin regions such as lips or genital regions.
- the present invention also relates to the use of the active principle of the above compositions, i.e. the glycopropylene ester of retinoic acid, in the preparation of pharmaceutical compositions for local destructive treatment of tumorous cells.
- the same active principle may also be used in the preparation of pharmaceutical compositions administered orally for the treatment of nerve disorders.
- Experiments conducted by the Applicant have, in fact, shown positive results in several patients suffering from various disorders of the nervous system and to whom a composition in accordance with the invention was administered orally. Though an in-depth toxicological investigation has not yet been conducted, oral administration of such compositions would appear to pose no toxicity problems. Indeed, retinoic acid and hydroquinone are already administered orally, and propylene glycol is also nontoxic at the low concentrations of the compositions according to the invention.
- solution A A first solution, referred to as “solution A”, is prepared with the following composition: retinoic acid 0.89 g hydroquinone 50 g ethyl alcohol 400 ml propylene glycol 400 ml
- solution A A second solution, referred to as “solution A”, is prepared with the following composition: retinoic acid 1 g hydroquinone 28 g propylene glycol 530 ml
- an esterification reaction between the alcohols and the acid is produced and accelerated, in the first case, by adding 1-3 drops of thionyl chloride to the solution as a catalyst, and, in the second case, by heating the solution to boiling point for 10-15 minutes.
- the reaction may of course be catalyzed by other acid catalysts, such as hydrochloric or salicylic acid.
- the two solutions are then mixed together to a ratio of 1:1.325 to form a third solution, referred to as “solution S”, which may be stored in a refrigerator and remains stable and active for 1-5 years.
- solution S in Example 1 clinical tests were conducted of a test group of 30 patients affected with various types of unsightly skin disorders and/or diseases. More specifically, using a wad of cotton, a very small amount of solution S (2 ml for the face) is applied to the skin and, in the space of 2-3 days, produces a peeling effect (desquamation of the surface layers of the skin) lasting about 12-48 hours. This is at times preceded by reddening of the skin and a slight heating sensation, which ceases when the skin peels. The treatment may be repeated twice a week.
- solution S in a second test group of 30 patients with more serious disorders, the solution was applied daily for 6-20 days.
- a fifth group of 30 patients with accident and/or surgical operation scars were treated with solution S once or twice a week and, at the same time, with a 5% cream for a period of 3 to 6 months. A marked improvement was seen in both old and new scars. Solution S was also experimented on the above patients with a weekly application to the abdomen, breasts and buttocks for 6-10 weeks, and resulted in smooth skin and a marked attenuation of stretch marks.
- the disorder is cured first on the face, then on the back, chest and arms, and finally on the legs and buttocks.
- Solution M was also used for locally treating external anal rhagades. 1 cc of the solution was applied locally once a day, two days a week, and brought about a complete cure in 2-4 weeks.
- a test group of 1300 patients were treated with solutions S and M and a solution D identical to S but containing no hydroquinone, and using the solutions as such and in the form of cream.
- solution S provides for enhancing the anti-inflammatory effects of commercial medicinal products of niflumic acid 3% (cream), indomethacin 1% (gel) and naproxene 10% (gel); for enhancing the anti-edema effect of sodium heparin (gel); for producing an antipruritic effect with an aqueous extract of tritiam vulgaris (cream); for improving the anti-pityriasis effect of terbinafin 1% (cream); and for improved treatment of herpes simplex with aciclovir 5% (cream).
- Solution M in a 2% cream and Diazepam 50 mg has a sedating-tranquillizing effect, which, however, still remains to be confirmed by parallel placebo testing.
- Solution S diluted in a 1% water solution and applied to the scalp once a day for several months arrests falling hair, eliminates dandruff and itching, and, after about 1 month, stimulates the growth of hair in regions affected by baldness.
- Solution S diluted up to 30 times in propylene glycol was also tested on delicate regions such as lips and genitals, or in the case of a particularly intense response, and confirmed the above results.
- compositions comprising: retinoic acid 2 g, salicylic acid 2-20 g, hydroquinone 10-50 g, and propylene glycol diluent 1000 ml. Some were esterified at ambient temperature, and others by heating to boiling point. When tested clinically, the resulting solutions, both as such and diluted in ethyl alcohol, appeared more active than those of similar composition in the previous Examples. Compositions identical to the above, but using a diluent of ethyl alcohol as opposed to propylene glycol, were also prepared. When esterified, the resulting solutions proved particularly effective in curing specific cases of eczema.
- solution G The resulting solution, referred to as “solution G”, was administered orally to a test group of 55 patients suffering from various disorders of the nervous system, in particular cerebral ictus, senile cerebral atrophy, Alzheimer's disease, grave amnesia, suicidal depression, and serious peripheral neurological disorders. Children and patients in pregnancy were excluded.
- a test group of patients suffering from the after-effects of cerebral ictus were administered orally with 1 cc of the solution every day for 15 days, and then 2-3 times a week. A marked improvement was observed in facial paralysis and ambulation, and a gradual improvement in the use of the affected leg. In patients suffering from acute cerebral ictus, daily administration of 4 cc of the solution seems to afford cerebral protection against necrosis.
- Results showed a rapid improvement in patients suffering from pains caused by peripheral neural disorders, and a complete return to normal in patients suffering from sensitivity disorders.
- Results also showed a rapid elimination of headaches, relief from pain in patients suffering from lumbar arthrosis, and an improvement in hyperthyroidism.
- the solution has proved effective both at the initial and maintenance stages, even when diluted to a ratio of 1:16, and particularly if administered several times a day, up to a 0.001% by weight concentration of propylene glycol ester of retinoic acid.
- Solution G alone or mixed to a ratio of 4:1 with solution M in Example 3, was also experimented in the local treatment of urogenital disturbances.
- Solution G has also proved effective when esterified in the absence of a catalyst, and by heating the solution to boiling point in a small-bottomed vessel for 4 hours.
- compositions prepared as described in the previous examples were subjected to standard chromatographic analysis, and all showed the presence of the propylene glycol ester of retinoic acid.
- the compositions administered orally showed a 0.015 N concentration of the ester (undiluted solutions), which may therefore reasonably be assumed to constitute the active principle (or at least one of the active principles) of the compositions according to the invention.
- Said ester is believed to present highly effective anti-inflammatory properties, especially at low concentrations, and at the same time, especially if used at relatively high concentrations, to induce an aggressive tissue reaction such, for example, as to produce peeling of the skin and, as seen, the destruction of tumorous cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A method for destructive treatment of tumorous cells including the use of glycopropylene of retinoic acid in a pharmaceutical composition, a method for bladder irrigation having antitumoral properties including the use of a glycopropylene ester of retinoic acid together with a pharmaceutically compatible liquid vector, a method for treatment of nerve disorders including the use of a glycopropylene ester of retinoic acid for preparation of a pharmaceutical composition and a pharmaceutical composition for the same.
Description
- The present invention relates to cosmetic compositions which may be applied to any part of the skin of the human body, including the scalp and genital organs, for effectively reducing and/or gradually eliminating unsightly skin disorders such as stretch marks, acne, scars, dark spots and incipient baldness, and which are also highly effective in treating mycosis and psoriasis. The present invention also relates to a cosmetic method of employing such compositions.
- Many people suffer from unsightly skin disorders caused by diseases or deterioration of more or less extensive portions of the skin, e.g. acne, scars resulting from accidents, wrinkles, stretch marks, blackheads, dark spots, and which are often accompanied by excessive sebum secretion and, at times, by actual diseases often caused by mycotic infections such as psoriasis, pityriasis, onychomycosis, etc.
- At present, people suffering from such problems must use a variety of either medicinal or cosmetic products (antimycotics, wrinkle removers, etc.), each limited to the treatment of a specific disorder. Acne, for example, is treated using medicaments based on retinoic acid (tretinoin, isotretinoin), but which are indicated exclusively for the treatment of acne. In more It serious cases, again of acne for example, recourse must be made to surgery to remove the affected skin portions, owing to the failure of known medicinal remedies not only to arrest the disease but also to even partly repair the damage already produced to the skin.
- It is an object of the present invention to provide a cosmetic and, at the same time, antimycotic composition capable of regenerating the affected skin regions and so gradually reducing and eventually attenuating and/or eliminating the above disorders.
- It is a further object of the present invention to provide cosmetic compositions which, in addition to being cosmetic, are also highly effective in the treatment of psoriasis, even severe, recurrent cases involving extensive skin regions.
- According to the present invention, there is provided a cosmetic, antimycotic composition for skin application, in particular for treating unsightly skin disorders such as acne, stretch marks, scars and dark spots;
- characterized by comprising at least a glycol or glyceric ester of retinoic acid dissolved in a glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solution.
- Preferably, the composition also comprises, in combination, the ethyl ester of retinoic acid and hydroquinone, both also dissolved in said glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solution.
- More specifically, said glyco-alcohol solution comprises propylene glycol and, in lesser proportions, ethyl alcohol; and also contains propylene glycol ether.
- In the case in point, one composition according to the invention comprises a glyco-alcohol solution of 0.10 to 0.25 N of ethyl ester of retinoic acid, and 0.15 to 0.30 N of glycopropylene ester of retinoic acid. Preferably, said glyco-alcohol solution presents a propylene glycol base, and also contains 0.001 to 0.002 N of ethyl-glycopropylene ether.
- As stated in the introduction, retinoic acid as such is already known as a product for the treatment of acne, and is preferably obtained from its ethyl ester. Its direct “clinical” use, however, in the form of ethyl and, more especially, glycopropyl ester, and its association with hydroquinone in a glyco- and/or hydro-alcohol solution, are entirely new, and have surprisingly resulted in a product which is equally effective in the treatment of any other unsightly skin disorder, and which produces a marked peeling effect (desquamation of the surface layers of the skin) with a visible improvement in the tone, firmness and luminosity of the skin, a visible reduction of small wrinkles, and a marked reduction of deeper wrinkles, together with a reduction in excess sebum secretion.
- In the case of acne, repeated use of the composition according to the invention provides for a marked improvement after only a few applications (five on average) and eventually total elimination. The composition according to the invention is also a highly effective antimycotic for curing diseases such as pityriasis, versicolor and onychomycosis after only two/four applications (one a week), and also provides for a marked improvement and for eventually curing psoriasis.
- Clinical tests have shown no appreciable side effects, with the exception of individual hypersensitivity to one of the components, and headaches accompanied or not by itching of the treated parts in the case of product abuse.
- The composition according to the invention may be marketed and used in the form of a solution applied using cotton cloth, cotton-wool, tissues or sponges soaked in the solution, or may comprise solid or semisolid excipients in which the glyco-alcohol solution is dispersed to form a cream, in which case, however, the peeling effect is reduced or entirely eliminated.
- According to a preferred embodiment of the present invention, the composition therefore also comprises solid or semisolid excipients in which 2-10% by weight of said glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solution of said esters of retinoic acid is dispersed, so that the composition according to the invention is in the form of a cream.
- The composition according to the invention may optionally comprise a cortisone, an anti-inflammatory substance, one or more liposoluble vitamins, and salicylic acid as such or in the form of glycol ester. More specifically, said anti-inflammatory substance is selected from the group comprising: niflumic acid, indomethacin and naproxene.
- Alternatively, the composition according to the invention may comprise sodium heparin in gel form to enhance the anti-edema effect.
- The composition according to the invention is prepared by producing an esterification reaction between retinoic acid and propylene glycol in a glyco-alcohol solution with a large excess of propylene glycol, so that substantially all the retinoic acid in the solution is esterified; and, after the esterification reaction, the solution is used as such, without removing the surplus reactants or the reaction products. The reaction is preferably conducted in the presence of 1.35% to 23.9% by weight of hydroquinone in the glyco-alcohol solution, and by catalyzing the reaction by heating the reaction mixture and/or by performing the reaction in the presence of an acid substance, e.g. salicylic acid, hydrochloric acid or thionyl chloride.
- It is a further object of the present invention to provide cosmetic methods of treating unsightly skin disorders such as acne, scars, stretch marks and dark spots, and enabling results at various levels ranging from simply invigorating “healthy” skin to gradually attenuating (and eventually eliminating or practically eliminating) the disorder.
- In general, a cosmetic method in accordance with the present invention is characterized in that:
- a glycol or glyceric ester of retinoic acid is prepared in a glyco-alcohol solution by esterifying the acid with the corresponding polyalcohol and operating with a large excess of polyalcohol in the presence of hydroquinone; and
- the resulting solution, containing the ester produced by the reaction, and possibly aged in atmospheric air at ambient temperature, is subsequently applied to the skin region for treatment to produce surface peeling of the region.
- According to a first embodiment of the above cosmetic method, the glycopropylene ester of retinoic acid is prepared in a first solution comprising propylene glycol as the only solvent and containing 0 to 8.5% by weight, of the total weight of the solution, of hydroquinone, by dissolving, in said solution, 0.01 to 4% by weight, of the total weight of the solution, of retinoic acid; and said solution containing the prepared ester is subsequently applied to the skin region for treatment.
- According to a second embodiment of the cosmetic method according to the invention, a mixture of glycopropylene and ethyl esters of retinoic acid is prepared in a second solution comprising equal proportions by volume of ethyl alcohol and propylene glycol as solvents and containing 1 to 13% by weight, of the total weight of the solution, of hydroquinone, by dissolving, in said solution, 0.01 to 0.13% by weight, of the total weight of the solution, of retinoic acid; and said solution containing the prepared mixture of esters is then applied to the skin region for treatment.
- According to a third embodiment of the cosmetic method according to the invention, said solutions containing the reaction products and formed as in the previous embodiments are mixed together to a predetermined ratio; the resulting solution being stored stably in a refrigerator, and being applied in a predetermined quantity to the skin region by means of a sponge, cotton cloth, cotton-wool or any other appropriate means soaked in the solution.
- The two solutions are preferably mixed to a ratio of 1:1 to 1:1.5 by volume.
- The combined solution formed in the third embodiment of the cosmetic method according to the invention is applied once a day for a period of 6 to 10 days, said application cycle being repeatable after a suspension of 4 to 6 months, or is applied twice a week for 6 to 7 weeks. Alternatively, appropriate excipients may be added to the combined solution to form a cream containing 2 to 10% by weight of said solution; and the cream is applied as such, with no appreciable peeling effect, once a day for a period of 3 to 6 months. optionally, the solution and the cream may be applied jointly in the amounts and in the manner prescribed.
- According to a variation of the cosmetic method according to the invention, said esterification reaction may be performed in the absence of hydroquinone in said glyco-alcohol solution, or by subsequently eliminating the hydroquinone from said reaction solution; the resulting solution then being diluted up to 30 times in propylene glycol and used to treat particularly delicate skin regions such as lips or genital regions.
- The present invention also relates to the use of the active principle of the above compositions, i.e. the glycopropylene ester of retinoic acid, in the preparation of pharmaceutical compositions for local destructive treatment of tumorous cells.
- Finally, the same active principle may also be used in the preparation of pharmaceutical compositions administered orally for the treatment of nerve disorders. Experiments conducted by the Applicant have, in fact, shown positive results in several patients suffering from various disorders of the nervous system and to whom a composition in accordance with the invention was administered orally. Though an in-depth toxicological investigation has not yet been conducted, oral administration of such compositions would appear to pose no toxicity problems. Indeed, retinoic acid and hydroquinone are already administered orally, and propylene glycol is also nontoxic at the low concentrations of the compositions according to the invention.
- Further characteristics and advantages of the invention will be made clear in the following examples of a number of non-limiting embodiments.
- A first solution, referred to as “solution A”, is prepared with the following composition:
retinoic acid 0.89 g hydroquinone 50 g ethyl alcohol 400 ml propylene glycol 400 ml - A second solution, referred to as “solution A”, is prepared with the following composition:
retinoic acid 1 g hydroquinone 28 g propylene glycol 530 ml - In both of the above solutions, an esterification reaction between the alcohols and the acid is produced and accelerated, in the first case, by adding 1-3 drops of thionyl chloride to the solution as a catalyst, and, in the second case, by heating the solution to boiling point for 10-15 minutes. As opposed to thionyl chloride, the reaction may of course be catalyzed by other acid catalysts, such as hydrochloric or salicylic acid. The two solutions are then mixed together to a ratio of 1:1.325 to form a third solution, referred to as “solution S”, which may be stored in a refrigerator and remains stable and active for 1-5 years.
- Using solution S in Example 1, clinical tests were conducted of a test group of 30 patients affected with various types of unsightly skin disorders and/or diseases. More specifically, using a wad of cotton, a very small amount of solution S (2 ml for the face) is applied to the skin and, in the space of 2-3 days, produces a peeling effect (desquamation of the surface layers of the skin) lasting about 12-48 hours. This is at times preceded by reddening of the skin and a slight heating sensation, which ceases when the skin peels. The treatment may be repeated twice a week.
- In a second test group of 30 patients with more serious disorders, the solution was applied daily for 6-20 days. A third test group of 30 patients were given a daily evening application of solution S in the form of a cream with 4% by weight of active substance (solution S), and 2% by weight for patients with sensitive skins. In no case was peeling produced.
- All three test groups treated as described above showed a visible improvement in skin tone, firmness and luminosity, accompanied by elimination of small wrinkles, a marked improvement in deeper wrinkles, and a gradual reduction of dark spots, excess sebum secretion and oiliness.
- A fourth group of patients affected with acne and selected from the above three test groups underwent a combined treatment of a facial application of solution S twice a week for 6-7 weeks, followed by application of the 4% cream for 3 months. All patients showed a regression in the disease.
- A fifth group of 30 patients with accident and/or surgical operation scars were treated with solution S once or twice a week and, at the same time, with a 5% cream for a period of 3 to 6 months. A marked improvement was seen in both old and new scars. Solution S was also experimented on the above patients with a weekly application to the abdomen, breasts and buttocks for 6-10 weeks, and resulted in smooth skin and a marked attenuation of stretch marks.
- Patients from the above five groups with scars on various parts of the body were treated with solution S two or three times a week, and every evening with a cream of 5-8% by weight of solution S. In 80-90% of the patients, second- and third-degree burn scars regressed in 3-6 months.
- In the same way as in Example 1, a solution “M” was prepared with the following composition:
retinoic acid 2.5 g hydroquinone 109 g propylene glycol 1000 ml - Patients selected from the five groups in Example 2 and suffering from mycotic infections were treated with solution M once or twice a week for 1-2 weeks. In all cases, a marked antimycotic action was observed, and patients suffering from pityriasis, versicolor or onychomycosis were cured completely.
- Thirty patients, 12 of whom in serious conditions, with psoriasis on all parts of the body and treated for several years with various available therapies, were treated with solution M and solution S in Example 1, as follows:
- two applications a week of solution S and simultaneous application of cream with 6-10% of solution S for 1-4 months;
- in more stubborn cases, the cycle was repeated with solution M as opposed to S.
- The disorder is cured first on the face, then on the back, chest and arms, and finally on the legs and buttocks.
- The whole body was treated, even lesions which had already been cured, and the treatment was continued for 1-2 months after the cure, in that relapses are frequent, though the newly formed lesions are less noticeable than before.
- In the case of psoriasis of the nails, only the solution was applied once a day for 3-4 months. Nail growth was accelerated, and the liquid was seen to selectively blacken the affected regions while leaving the healthy regions their natural color.
- Patients suffering from psoriasis of the scalp were also treated 3 times a week with solution S diluted 6% by weight in propylene glycol, and washing the hair 15 minutes after the application.
- In all cases, itching, smarting and discomfort were eliminated immediately.
- Solution M was also used for locally treating external anal rhagades. 1 cc of the solution was applied locally once a day, two days a week, and brought about a complete cure in 2-4 weeks.
- A test group of 1300 patients were treated with solutions S and M and a solution D identical to S but containing no hydroquinone, and using the solutions as such and in the form of cream.
- The same results as in Examples 2 and 3 were observed, with absolutely no side effects. Patients in pregnancy or with skin tumors or allergies were not tested. The solution in cream form provides for improving the skin but has no appreciable peeling effect.
- The addition of small amounts of solution S (2 ml) provides for enhancing the anti-inflammatory effects of commercial medicinal products of niflumic acid 3% (cream), indomethacin 1% (gel) and naproxene 10% (gel); for enhancing the anti-edema effect of sodium heparin (gel); for producing an antipruritic effect with an aqueous extract of tritiam vulgaris (cream); for improving the anti-pityriasis effect of terbinafin 1% (cream); and for improved treatment of herpes simplex with aciclovir 5% (cream).
- Solution M in a 2% cream and Diazepam 50 mg has a sedating-tranquillizing effect, which, however, still remains to be confirmed by parallel placebo testing. Solution S diluted in a 1% water solution and applied to the scalp once a day for several months arrests falling hair, eliminates dandruff and itching, and, after about 1 month, stimulates the growth of hair in regions affected by baldness.
- Solution S diluted up to 30 times in propylene glycol was also tested on delicate regions such as lips and genitals, or in the case of a particularly intense response, and confirmed the above results.
- A number of compositions were prepared comprising: retinoic acid 2 g, salicylic acid 2-20 g, hydroquinone 10-50 g, and propylene glycol diluent 1000 ml. Some were esterified at ambient temperature, and others by heating to boiling point. When tested clinically, the resulting solutions, both as such and diluted in ethyl alcohol, appeared more active than those of similar composition in the previous Examples. Compositions identical to the above, but using a diluent of ethyl alcohol as opposed to propylene glycol, were also prepared. When esterified, the resulting solutions proved particularly effective in curing specific cases of eczema.
- In a solution of 1 g of retinoic acid in 150 ml of propylene glycol, the acid was esterified by adding 1 mg of salicylic acid as a catalyst, and heating the solution to boiling point in a wide-bottomed vessel.
- The resulting solution, referred to as “solution G”, was administered orally to a test group of 55 patients suffering from various disorders of the nervous system, in particular cerebral ictus, senile cerebral atrophy, Alzheimer's disease, grave amnesia, suicidal depression, and serious peripheral neurological disorders. Children and patients in pregnancy were excluded.
- A test group of patients suffering from the after-effects of cerebral ictus were administered orally with 1 cc of the solution every day for 15 days, and then 2-3 times a week. A marked improvement was observed in facial paralysis and ambulation, and a gradual improvement in the use of the affected leg. In patients suffering from acute cerebral ictus, daily administration of 4 cc of the solution seems to afford cerebral protection against necrosis.
- Patients of over 90 years of age were administered 1 cc of solution every day for 10 days, then 2-3 times a week for 4 weeks, and finally once a week. Results showed an improvement in memory and cognitive capacity, and a reduction in anxiety and depression. An overall improvement in psychic condition was also observed in depressed, anxiety-prone and even suicidal patients subjected to the same treatment.
- Improvements were also observed in the ambulation of patients affected with nerve disorders as a result of AIDS, and in the respiration of patients affected with chronic asthmatic bronchitis.
- Epileptic patients administered with 1 cc a day of the solution showed a reduction in epileptic fits and an overall improvement in psychic condition.
- A 12-year-old patient affected with Rett's syndrome, and suffering from paralysis of the legs for six months, regained use of the legs with a very small dose of the solution administered every other day.
- Results showed a rapid improvement in patients suffering from pains caused by peripheral neural disorders, and a complete return to normal in patients suffering from sensitivity disorders.
- Results also showed a rapid elimination of headaches, relief from pain in patients suffering from lumbar arthrosis, and an improvement in hyperthyroidism.
- The solution also seems to afford protection in cases of heart attack accompanied by arrhythmia, and to accelerate the healing of bone fractures (a thigh-bone fracture of a 5-year-old dog was healed after only 5 days'treatment). Finally, a patient suffering from pulmonary metastasis as a result of breast cancer, and already operated two years previously, was cured.
- The solution has proved effective both at the initial and maintenance stages, even when diluted to a ratio of 1:16, and particularly if administered several times a day, up to a 0.001% by weight concentration of propylene glycol ester of retinoic acid.
- The only side effects observed were headache and drowsiness in two patients subjected to high-dose treatment (15 cc), and the appearance of brown skin marks in a third patient.
- Blood tests conducted after 2-3 months of daily treatment proved normal.
- Solution G, alone or mixed to a ratio of 4:1 with solution M in Example 3, was also experimented in the local treatment of urogenital disturbances.
- In one case of trigone cancer, irrigation of the bladder with 5 cc of solution G once a day for 10 days and subsequently twice a week produced an inflammatory leuko-lymphocytic reaction, with necrosis and breakdown of the tumor, and a cure after two months'treatment, as confirmed by cytoscopic and biopsy tests.
- In a female patient with a trigone polyp, daily irrigation of the bladder with 5 cc of solution G mixed to a ratio of 4:1 with solution M in Example 3 brought about the destruction and elimination of the polyp after only one week's treatment.
- Several other patients subjected to the same treatment showed improvements in the functioning of the neck of the bladder, bladder contraction, cystitis, prostate hypertrophy, urine discharge and post-urination residue. One case of regressed ejaculation as a result of radiation therapy was restored to normal in one week. vaginal application of 1 cc of solution G brought about a reduction in vaginitis and vaginal itching, and elderly patients showed an overall improvement in the vaginal mucous membrane.
- Solution G has also proved effective when esterified in the absence of a catalyst, and by heating the solution to boiling point in a small-bottomed vessel for 4 hours.
- The solutions prepared as described in the previous examples were subjected to standard chromatographic analysis, and all showed the presence of the propylene glycol ester of retinoic acid. In particular, the compositions administered orally showed a 0.015 N concentration of the ester (undiluted solutions), which may therefore reasonably be assumed to constitute the active principle (or at least one of the active principles) of the compositions according to the invention.
- Said ester is believed to present highly effective anti-inflammatory properties, especially at low concentrations, and at the same time, especially if used at relatively high concentrations, to induce an aggressive tissue reaction such, for example, as to produce peeling of the skin and, as seen, the destruction of tumorous cells.
- Chromatographic analysis also confirmed, when present, the effective catalytic action of salicylic acid (the salts and esters of this acid are only present in very low concentrations) and the stabilizing and antioxidizing effect of hydroquinone.
Claims (31)
1. A cosmetic, antimycotic composition for skin application, in particular for treating unsightly skin disorders such as acne, stretch marks, scars and dark spots;
characterized by comprising at least a glycol or glyceric ester of retinoic acid dissolved in a glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solution.
2. A composition as claimed in claim 1 , characterized by comprising the glycopropylene ester of retinoic acid.
3. A composition as claimed in claim 1 or 2, characterized by also comprising, in association with said glycol or glyceric ester, the ethyl ester of retinoic acid, also dissolved in said glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solution.
4. A composition as claimed in one of the foregoing claims, characterized by also comprising hydroquinone, which is dissolved in said glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solution together with said esters of retinoic acid.
5. A composition as claimed in one of the foregoing claims, characterized in that said glyco-alcohol solution comprises propylene glycol and, in lesser proportions, ethyl alcohol.
6. A composition as claimed in one of the foregoing claims, characterized in that said glyco-alcohol solution also contains propylene glycol ether.
7. A composition as claimed in any one of the foregoing claims, characterized by comprising a glyco-alcohol solution of 0.10 to 0.25 N of ethyl ester of retinoic acid and 0.15 to 0.30 N of glycopropylene ester of retinoic acid.
8. A composition as claimed in claim 7 , characterized in that said glyco-alcohol solution presents a propylene glycol base, and also contains 0.001 to 0.002 N of ethyl-glycopropylene ether.
9. A composition as claimed in any one of the foregoing claims, characterized by comprising solid or semisolid excipients in which 2 to 10% by weight of said glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solution of said esters of retinoic acid is dispersed, so that said composition is in the form of a cream.
10. A composition as claimed in any one of the foregoing claims, characterized by also comprising a substance selected from the group comprising: a cortisone, an anti-inflammatory substance, one or more liposoluble vitamins, salicylic acid, the glycopropylene ester of salicylic acid, and mixtures thereof.
11. A composition as claimed in claim 10 , characterized in that said anti-inflammatory substance is selected from the group comprising: niflumic acid, indomethacin, and naproxene.
12. A composition as claimed in any one of the foregoing claims, characterized by also comprising sodium heparin in gel form.
13. A method of preparing a cosmetic, antimycotic composition as claimed in one of the foregoing claims, characterized by comprising the steps of:
producing an esterification reaction between retinoic acid and propylene glycol in a glyco-alcohol solution with a large excess of propylene glycol, so that substantially all the retinoic acid in the solution is esterified; and
using said solution as such, at the end of the esterification reaction, without removing the surplus reactants or the reaction products.
14. A method as claimed in claim 13 , characterized in that said esterification reaction is conducted in the presence of 1.35 to 23.9% by weight of hydroquinone dissolved in said glyco-alcohol solution.
15. A method as claimed in claim 13 or 14, characterized in that said esterification reaction is accelerated in the presence of an acid catalyst and/or by heating the reaction mixture.
16. A method as claimed in claim 15 , characterized in that said acid catalyst is salicylic acid.
17. A method as claimed in claim 15 , characterized in that said acid catalyst is thionyl chloride.
18. A cosmetic method of treating unsightly skin disorders such as acne, scars, stretch marks and dark spots, characterized in that:
a glycol or glyceric ester of retinoic acid is prepared in a glyco-alcohol solution by esterifying the acid with the corresponding polyalcohol and operating with a large excess of polyalcohol in the presence of hydroquinone; and
the resulting solution, containing the ester produced by the reaction, and possibly aged in atmospheric air at ambient temperature, is applied to the skin region for treatment to produce surface peeling of the region.
19. A cosmetic method of treating unsightly skin disorders such as acne, scars, stretch marks and dark spots, characterized in that:
the glycopropylene ester of retinoic acid is prepared in a solution comprising propylene glycol as the only solvent and containing 0 to 8.5% by weight, of the total weight of the solution, of hydroquinone, by dissolving, in said solution, 0.01 to 4% by weight, of the total weight of the solution, of retinoic acid; and
said solution containing the prepared ester is applied to the skin region for treatment.
20. A cosmetic method of treating unsightly skin disorders such as acne, scars, stretch marks and dark spots, characterized in that:
a mixture of glycopropylene and ethyl esters of retinoic acid is prepared in a solution comprising equal proportions by volume of ethyl alcohol and propylene glycol as solvents and containing 1 to 13% by weight, of the total weight of the solution, of hydroquinone, by dissolving, in said solution, 0.01 to 0.13% by weight, of the total weight of the solution, of retinoic acid; and
said solution containing the prepared mixture of esters is applied to the skin region for treatment.
21. A cosmetic method of treating unsightly skin disorders such as acne, scars, stretch marks and dark spots, characterized in that said solutions containing the reaction products and formed according to the methods claimed in claims 19 and 20 are mixed together to a predetermined ratio; the resulting solution being stored stably in a refrigerator, and being applied in a predetermined quantity to the skin region for treatment by means of a sponge, cotton cloth, cotton-wool or any other appropriate means soaked in the solution.
22. A cosmetic method as claimed in claim 21 , characterized in that the two solutions are mixed to a ratio of 1:1 to 1:1.5 by volume.
23. A cosmetic method as claimed in claim 21 or 22, characterized in that the solution is applied:
once a day for 6-10 days; said application cycle being repeatable after a suspension of 4-6 months; or:
twice a week for 6-7 weeks.
24. A cosmetic method as claimed in claim 21 or 22, characterized in that said resulting solution is converted, by the addition of appropriate excipients, into a cream containing 2 to 10% by weight of said solution, and is applied as such, with no appreciable peeling effect, once a day for 3-6 months.
25. A cosmetic method of treating unsightly skin disorders such as acne, scars, stretch marks and dark spots, characterized in that the methods claimed in claims 23 and 24 are applied jointly.
26. A cosmetic method as claimed in claim 20 or 21, characterized in that said esterification reaction is conducted in the absence of hydroquinone in said glyco-alcohol solution, or by subsequently eliminating the hydroquinone from said reaction solution; the resulting solution then being up to diluted 30 times in propylene glycol, and used for treating particularly delicate skin regions such as lips and genital regions.
27. Use of the glycopropylene ester of retinoic acid for the preparation of a pharmaceutical composition for local destructive treatment of tumorous cells.
28. Use of the glycopropylene ester of retinoic acid, together with a liquid vector pharmaceutically compatible with said ester, for the preparation of a therapeutic solution for bladder irrigation and presenting antitumoral properties.
29. Use of the glycopropylene ester of retinoic acid for the preparation of a pharmaceutical composition administered orally for the treatment of nerve disorders.
30. Use as claimed in claim 29 , characterized in that said pharmaceutical composition contains a concentration of 0.0015 to 0.20 N of said ester.
31. A pharmaceutical composition, characterized by comprising as an active principle the glycopropylene ester of retinoic acid in association with excipients pharmaceutically compatible with said ester.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/965,795 US20020037305A1 (en) | 1995-06-30 | 2001-10-01 | Cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT95TO000551A IT1276459B1 (en) | 1995-06-30 | 1995-06-30 | COSMETIC COMPOSITIONS WITH ANTIMICOTIC PROPERTIES, EFFECTIVE AGAINST PSORIASIS AND HAIR LOSS AND COSMETIC METHOD FOR |
ITTO95A000551 | 1995-06-30 | ||
PCT/IT1996/000129 WO1997002030A1 (en) | 1995-06-30 | 1996-06-27 | A cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders |
US08/997,986 US6319957B1 (en) | 1995-06-30 | 1997-12-24 | Method for treating skin |
US09/965,795 US20020037305A1 (en) | 1995-06-30 | 2001-10-01 | Cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/997,986 Division US6319957B1 (en) | 1995-06-30 | 1997-12-24 | Method for treating skin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020037305A1 true US20020037305A1 (en) | 2002-03-28 |
Family
ID=11413690
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/997,986 Expired - Fee Related US6319957B1 (en) | 1995-06-30 | 1997-12-24 | Method for treating skin |
US09/965,795 Abandoned US20020037305A1 (en) | 1995-06-30 | 2001-10-01 | Cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/997,986 Expired - Fee Related US6319957B1 (en) | 1995-06-30 | 1997-12-24 | Method for treating skin |
Country Status (6)
Country | Link |
---|---|
US (2) | US6319957B1 (en) |
EP (1) | EP0836476B1 (en) |
AU (1) | AU6241096A (en) |
DE (1) | DE69636778D1 (en) |
IT (1) | IT1276459B1 (en) |
WO (1) | WO1997002030A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9907461D0 (en) * | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
IT1304656B1 (en) * | 1998-09-23 | 2001-03-28 | Khodor Ammar | RETINOIC ACID DERIVATIVES FOR MEDICINAL USE AND RELATED METHOD OF PREPARATION. |
US6482943B1 (en) | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
WO2000066175A2 (en) | 1999-04-30 | 2000-11-09 | Slil Biomedical Corporation | Conjugates as therapies for cancer and prostate diseases |
DE60132436T2 (en) * | 2000-03-30 | 2008-04-17 | Oxford Biomedica (Uk) Ltd. | RETINOLIC ACID RECEPTOR BETA-2 AND GENETHERAPY VECTORS FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
WO2002091989A2 (en) | 2000-11-08 | 2002-11-21 | Slil Biomedical Corporation | Antiviral therapies using polyamine or polyamine analog-amino acid conjugates |
NZ516873A (en) * | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
US7189759B2 (en) * | 2001-05-23 | 2007-03-13 | Medicis Pharmaceutical Corporation | Compositions for the treatment of pigmentation disorders and methods for their manufacture |
US20090203628A1 (en) * | 2008-02-12 | 2009-08-13 | Jan Marini | Composition, Method And Kit For Treating Skin Disorders And Improving Skin Condition |
ES2327201B1 (en) * | 2008-04-23 | 2010-07-23 | Ignacio Umbert Millet | PERSONALIZED PHARMACEUTICAL COMPOSITION FOR THE REJUVENATION OF SKIN CONTAINING RETINOIC ACID. |
ES2378028B1 (en) | 2012-02-22 | 2013-02-18 | Ignacio Umbert Millet | Cosmetic composition for skin rejuvenation and corresponding procedure and uses |
US8603549B1 (en) | 2012-05-25 | 2013-12-10 | Svetlana Baker | Systems and methods for inhibiting formation of stretch marks |
EP3090741B1 (en) * | 2015-02-06 | 2019-07-10 | Orlandi, Augusto | The direct fungistatic effect of all-transretinoic acid on candida albicans and aspergillus fumigatus |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR472225A (en) | 1913-05-20 | 1914-11-26 | Azulay Syndicate Ltd | Improvements in machines for the manufacture of objects or of material composed of rubber or other adhesive material and fiber |
NL257621A (en) * | 1959-11-23 | |||
US4216224A (en) * | 1978-09-22 | 1980-08-05 | Scott Eugene J Van | Methods and compositions for treating psoriasis with retinoyl compounds |
US4247547A (en) * | 1979-03-19 | 1981-01-27 | Johnson & Johnson | Tretinoin in a gel vehicle for acne treatment |
US5514672A (en) * | 1981-02-17 | 1996-05-07 | Bazzano; Gail S. | Use of retinoids and compositions containing same for hair growth |
US4677120A (en) * | 1985-07-31 | 1987-06-30 | Molecular Design International | Topical prodrugs for treatment of acne and skin diseases |
FR2591105B1 (en) * | 1985-12-11 | 1989-03-24 | Moet Hennessy Rech | PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, OR COSMETIC, BASED ON HYDRATED LIPID LAMELLAR PHASES OR LIPOSOMES CONTAINING A RETINOIDE OR A STRUCTURAL ANALOG OF SUCH A RETINOID AS A CAROTENOID. |
US4885311A (en) * | 1987-06-29 | 1989-12-05 | Molecular Design International | Topical transretinoids for treatment of acne and skin diseases |
WO1989006977A1 (en) * | 1988-02-04 | 1989-08-10 | Board Of Regents, The University Of Texas System | Formulation and use of retinoids in treatment of cancer and other diseases |
US5043356A (en) * | 1990-01-19 | 1991-08-27 | Fulton Jr James E | Composition and method for rejuvenating skin using vitamin A propionate |
US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
GB9125712D0 (en) * | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Skin care composition |
US5686086A (en) * | 1992-07-13 | 1997-11-11 | Shiseido Co., Ltd. | External skin treatment composition |
-
1995
- 1995-06-30 IT IT95TO000551A patent/IT1276459B1/en active IP Right Grant
-
1996
- 1996-06-27 WO PCT/IT1996/000129 patent/WO1997002030A1/en active IP Right Grant
- 1996-06-27 AU AU62410/96A patent/AU6241096A/en not_active Abandoned
- 1996-06-27 DE DE69636778T patent/DE69636778D1/en not_active Expired - Lifetime
- 1996-06-27 EP EP96921075A patent/EP0836476B1/en not_active Expired - Lifetime
-
1997
- 1997-12-24 US US08/997,986 patent/US6319957B1/en not_active Expired - Fee Related
-
2001
- 2001-10-01 US US09/965,795 patent/US20020037305A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU6241096A (en) | 1997-02-05 |
DE69636778D1 (en) | 2007-02-01 |
EP0836476A1 (en) | 1998-04-22 |
EP0836476B1 (en) | 2006-12-20 |
ITTO950551A1 (en) | 1996-12-30 |
US6319957B1 (en) | 2001-11-20 |
IT1276459B1 (en) | 1997-10-31 |
ITTO950551A0 (en) | 1995-06-30 |
WO1997002030A1 (en) | 1997-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1663559B (en) | Skin normalizing agents | |
TW537900B (en) | A skin treatment comprising repeated topical application to structurally deteriorated skin of a skin water-vapor barrier disruption treatment effective to provide chronic disruption of the aged skin's water-vapor barrier said chronic disruption being | |
JP4832725B2 (en) | Carbon dioxide-containing viscous composition | |
JP4745608B2 (en) | Skin treatment using phosphoric acid derivatives of electron transfer agents | |
US5633284A (en) | Nitrous oxide containing dermatological composition | |
US6319957B1 (en) | Method for treating skin | |
EP0822816B1 (en) | Dermatological preparation for treating actinic keratoses | |
EP0531495B1 (en) | Therapeutic and cosmetic compositions for treatment of skin | |
US7655255B2 (en) | Topical composition for transdermal administration | |
US6544502B2 (en) | Skin treatment with a water soluble antibiotic dissolved in an electrolyzed water | |
US20060222689A1 (en) | Skin care compositions and methods | |
JP4243353B2 (en) | Zinc salt of conjugated linoleic acid for the treatment of skin diseases | |
US20020176876A1 (en) | Topical therapeutic skin care system | |
US20210236446A1 (en) | Wound healing composition | |
US20060115503A1 (en) | Composition, system and method for treatment of skin | |
US20050276766A1 (en) | Methods and compositions for increasing skin remodeling | |
CN106491512A (en) | A kind of bio protease new life essence cream | |
DE69013139T2 (en) | Means for the prevention, diagnosis and therapy of rheumatic, autoimmune, skin and connective tissue diseases of unknown etiology and methods for their preparation and use. | |
WO1997018804A1 (en) | Rejuvenating the skin using a combination of vitamin a and alphahydroxy acids | |
JPS5988421A (en) | Sebum spread reducing composition | |
DE2840173C2 (en) | Agent for the restoration of cell functions in the case of tissue defects of an infectious or degenerative nature, delayed wound healing, age-related symptoms and depressed moods | |
KR960015725B1 (en) | Hair Treatment Composition | |
CN118593624A (en) | A Chinese medicine composition for external use for treating acne and its application | |
Hurley | Treatment of acne vulgaris | |
BG63242B1 (en) | Dermatological gels for local therapy in acne vulgaris and in herpes simplex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |